Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
- PMID: 32128285
- PMCID: PMC7034025
- DOI: 10.1080/21556660.2020.1721507
Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
Abstract
Objective: To review the current evidence regarding pregnancy-related issues in multiple sclerosis (MS) and to provide recommendations specific for each of them. Research design and methods: A systematic review was performed based on a comprehensive literature search. Results: MS has no effect on fertility, pregnancy or fetal outcomes, and pregnancies do not affect the long-term disease course and accumulation of disability. There is a potential risk for relapse after use of gonadotropin-releasing hormone agonists during assisted reproduction techniques. At short-term, pregnancy leads to a reduction of relapses during the third trimester, followed by an increased risk of relapses during the first three months postpartum. Pregnancies in MS are not per se high risk pregnancies, and MS does not influence the mode of delivery or anesthesia unless in the presence of significant disability. MRI is not contraindicated during pregnancy; however, gadolinium contrast media should be avoided whenever possible. It is safe to use pulse dose methylprednisolone infusions to manage acute disabling relapses during pregnancy and breastfeeding. However, its use during the first trimester of pregnancy is still controversial. Women with MS should be encouraged to breastfeed with a possible favorable effect of exclusive breastfeeding. Disease-modifying drugs can be classified according to their potential for pregnancy-associated risk and impact on fetal outcome. Interferon beta (IFNβ) and glatiramer acetate (GA) may be continued until pregnancy is confirmed and, after consideration of the individual risk-benefit if continued, during pregnancy. The benefit of continuing natalizumab during the entire pregnancy may outweigh the risk of recurring disease activity, particularly in women with highly active MS. GA and IFNβ are considered safe during breastfeeding. The use of natalizumab during pregnancy or lactation requires monitoring of the newborn. Conclusions: This review provides current evidence and recommendations for counseling and management of women with MS preconception, during pregnancy and postpartum.
Keywords: Multiple sclerosis; breastfeeding; delivery; disease-modifying therapy; newborn; postpartum; pregnancy.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Similar articles
-
Breast cancer, pregnancy, and breastfeeding.J Obstet Gynaecol Can. 2002 Feb;24(2):164-80; quiz 181-4. J Obstet Gynaecol Can. 2002. PMID: 12196882 English, French.
-
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.JAMA Netw Open. 2022 Jan 4;5(1):e2144750. doi: 10.1001/jamanetworkopen.2021.44750. JAMA Netw Open. 2022. PMID: 35072719 Free PMC article.
-
Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):151-157. doi: 10.1136/jnnp-2023-331525. J Neurol Neurosurg Psychiatry. 2024. PMID: 37536925 Free PMC article.
-
Treatment of Women with Multiple Sclerosis Planning Pregnancy.Curr Treat Options Neurol. 2021;23(4):11. doi: 10.1007/s11940-021-00666-4. Epub 2021 Mar 30. Curr Treat Options Neurol. 2021. PMID: 33814892 Free PMC article. Review.
-
[Pregnancy and breastfeeding in women with multiple sclerosis].Nervenarzt. 2024 Apr;95(4):329-334. doi: 10.1007/s00115-024-01621-9. Epub 2024 Feb 23. Nervenarzt. 2024. PMID: 38393359 Review. German.
Cited by
-
Effect of Cladribine Tablets on the Pharmacokinetics of a Combined Oral Contraceptive in Pre-Menopausal Women With Relapsing Multiple Sclerosis.Clin Transl Sci. 2025 Apr;18(4):e70204. doi: 10.1111/cts.70204. Clin Transl Sci. 2025. PMID: 40170281 Free PMC article. Clinical Trial.
-
[Esclerosis multiple. Lactancia. Lactante. Planificacion familiar. Posparto. Tratamiento modificador de la enfermedad.].Rev Neurol. 2023 Jan 1;76(1):21-30. doi: 10.33588/rn.7601.2022404. Rev Neurol. 2023. PMID: 36544373 Free PMC article. Review. Spanish.
-
Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review.Front Neurol. 2022 Apr 15;13:851413. doi: 10.3389/fneur.2022.851413. eCollection 2022. Front Neurol. 2022. PMID: 35493841 Free PMC article. Review.
-
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis.CNS Drugs. 2023 Oct;37(10):849-866. doi: 10.1007/s40263-023-01036-1. Epub 2023 Sep 7. CNS Drugs. 2023. PMID: 37679579 Free PMC article. Review.
-
Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.Front Neurol. 2021 Jul 1;12:697974. doi: 10.3389/fneur.2021.697974. eCollection 2021. Front Neurol. 2021. PMID: 34276545 Free PMC article. Review.
References
-
- Confavreux C, Vukusic S.. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(3):606–616. - PubMed
-
- Compston A, Coles A.. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517. - PubMed
-
- Bove R, Chitnis T.. T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20(5):520–526. - PubMed
-
- Niedziela N, Adamczyk-Sowa M, Pierzchała K.. Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review. Int J Neurosci. 2014;124(5):322–330. - PubMed
-
- Rasmussen PV, Magyari M, Moberg JY, et al. . Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. Mult Scler Relat Disord. 2018;24:129–134. - PubMed
LinkOut - more resources
Full Text Sources